I
Ian O. Ellis
Researcher at University of Nottingham
Publications - 1071
Citations - 84964
Ian O. Ellis is an academic researcher from University of Nottingham. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 126, co-authored 1051 publications receiving 75435 citations. Previous affiliations of Ian O. Ellis include Mansoura University & Curie Institute.
Papers
More filters
Journal ArticleDOI
Best Practice No 176 : Updated recommendations for HER2 testing in the UK
Ian O. Ellis,John M. S. Bartlett,Mitchell Dowsett,S. Humphreys,Bharat Jasani,Keith Miller,Sarah E Pinder,Anthony Rhodes,Rosemary A. Walker +8 more
TL;DR: A two phase testing algorithm based on first line immunocytochemistry evaluation and second line fluorescence in situ hybridization assessment of borderline cases is recommended in this article, where emphasis is placed on the standardisation of methodology and assessment and strategies to achieve high quality performance.
Journal ArticleDOI
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Paul Ellis,Peter Barrett-Lee,L. Johnson,David Cameron,Andrew M Wardley,S O'Reilly,Mark Verrill,Ian E. Smith,John Yarnold,Robert E. Coleman,Helena M. Earl,Peter Canney,Chris Twelves,Christopher Poole,D. Bloomfield,Penelope Hopwood,Stephen S. Johnston,Mitchell Dowsett,John M. S. Bartlett,Ian O. Ellis,Clare Peckitt,Emma Hall,Judith M Bliss +22 more
TL;DR: This study did not show any overall gain from the addition of docetaxel to standard anthracycline chemotherapy, and exploration of predictive biomarker-defined subgroups might have the potential to better target the use of taxane-based therapy.
Journal ArticleDOI
Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates.
TL;DR: A review of the literature indicated variable underestimation rates for breast core-needle biopsy (CNB) based on generally small series was 27.7% (95% confidence interval [95% CI], 24.5-30.9% as mentioned in this paper.
Journal ArticleDOI
Improved Methods of Detection of Lymphovascular Invasion Demonstrate That It Is the Predominant Method of Vascular Invasion in Breast Cancer and Has Important Clinical Consequences
TL;DR: In conclusion, VI in breast cancer is predominantly of lymph vessels and is a powerful independent prognostic factor, which is associated with risk of recurrence and death from the disease.
Journal ArticleDOI
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial
Roger W. Blamey,Tom Bates,Udi Chetty,Stephen W. Duffy,Ian O. Ellis,David George,Elizabeth Mallon,M.J. Mitchell,I. Monypenny,D.A.L. Morgan,R.D. Macmillan,Julietta Patnick,Sarah E Pinder +12 more
TL;DR: Even in these patients with tumours of excellent prognosis, LR after conservative surgery without adjuvant therapy was still very high and was reduced to a similar extent by either radiotherapy or tamoxifen but to a greater extent by the receipt of both treatments.